Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression

Modern Pathology

Volumn 28, Issue 3, 2015, Pages 428-436

  Stewart, Jonathan ^a,b   James, Jacqueline ^a,b   McCluggage, Glenn W ^a,b   McQuaid, Stephen ^a,b   Arthur, Kenneth ^a   Boyle, David ^a,b   Mullan, Paul ^a   McArt, Darragh ^b   Yan, Benedict ^c   Irwin, Gareth ^a   Harkin, D Paul ^a   Zhengdeng, Lei ^d   Ong, Chee Wee ^a   Yu, Jia ^d   Virshup, David M ^d   Salto Tellez, Manuel ^a,b,c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; WNT PROTEIN; ERBB2 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; GPR177 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; STOMACH CANCER; TUMOR VOLUME; WNT SIGNALING PATHWAY; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA; KAPLAN MEIER METHOD; MALE; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; STOMACH TUMOR; TISSUE MICROARRAY;

BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, G-PROTEIN-COUPLED; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84925812252     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.114     Document Type: Article

References (59)

1. Bänziger C, Soldini D, Schü tt C, et al. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell 2006;125:509-522
2. Bartscherer K, Pelte N, Ingelfinger D, et al. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell 2006;125:523-533
3. Belenkaya TY, Wu Y, Tang X, et al. The retromer complex influences Wnt secretion by recycling Wntless from endosomes to the trans-golgi network. Dev Cell 2008;14:120-131
4. Coombs GS, Yu J, Canning CA, et al. WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification. J Cell Sci 2010;123:3357-3367
5. Najdi R, Proffitt K, Sprowl S, et al. A uniform human Wnt expression library reveals a shared secretory pathway and unique signaling activities. Differentiation 2012;84:203-213
6. Augustin I, Goidts V, Bongers A, et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumorigenesis. EMBO Mol Med 2012;4:38-51
7. Bafico A, Liu G, Goldin L, et al. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004;6:497-506
8. Rask K, Nilsson A, Brannstrom M, et al. Wnt-signalling pathway in ovarian epithelial tumors: increased expression of beta-catenin and GSK3beta. Br J Cancer 2000;89:1298-1304
9. Badiglian Filho L, Oshima C, De Oliveira-Lima F, et al. Canonical and non canonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 2009;21:313-320
10. Nakatsuru S, Yanagisawa A, Ichii S, et al. Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum Mol Genet 1992;1:559-563
11. Ebert MPA, Fei G, Kahmann S, et al. Increased bcatenin mRNA levels and mutational alterations of the APC and b-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 2002;23:87-91
12. Pan K, Liu W, Zhang l, et al. Mutations in components of the Wnt signaling pathway in gastric cancer. World J Gastroentero 2008;14:1570-1574
13. Lin S, Xia W, Wang JC, et al. b-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000;97:4262-4266
14. Schlosshauer PW, Brown SA, Eisinger K, et al. APC truncation and increased b-catenin levels in a human breast cancer cell line. Carcinogenesis 2000;21: 1453-1456
15. Jönsson M, Borg A , Nilbert M, et al. Involvement of adenomatous polyposis coli (APC)/b-catenin signalling in human breast cancer. Eur J Cancer 2000;36: 242-248
16. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-842
17. Wang T, Ong CW, Shi J, et al. Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer 2011;105:658-665
18. Das K, Mohd Omar M, Ong C, et al. TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. Pathology 2008;40:441-449
19. Salto-Tellez M, Nga ME, Han HC, et al. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumors. Br J Cancer 2007;96:776-782
20. Fassina A, Cappellesso R, Guzzardo V, et al. Epithelialmesenchymal transition in malignant mesothelioma. Mod Pathol 2012;25:86-99
21. Cavicchioli Buim ME, Gurgel CAS, Gonçalves Ramos EA, et al. Activation of sonic hedgehog signaling in oral squamous cell carcinomas: a preliminary study. Hum Pathol 2011;42:1484-1490
22. Prat J. Ovarian Carcinomas: Five distinct disease with different origins, genetic alterations and clinicopatholoigcal features. Virchows Arch 2012;460:237-249
23. Gatcliffe T, Monk B, Planutis K, et al. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008;18: 954-962
24. Howe L, Brown A. Wnt signaling and Breast Cancer. Cancer Biol Ther 2004;3:36-41
25. Wright K, Wilson P, Morland S, et al. Beta-Catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumors. Int J Cancer 1999;82:625-629
26. Ebert MPA, Yu J, Hoffmann J, et al. Loss of Beta-Catenin Expression in Metastatic Gastric Cancer. J Clin Oncol 2003;21:1708-1714
27. Ogasawara N, Tsukamoto T, Mizoshita T, et al. Mutations and nuclear accumulation of Beta-catenin correlate with intestinal phenotypic expression in human gastric cancer. Histopathology 2006;49:612-621
28. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-Protein Overexpression in Breast Cancer. N Engl J Med 1988;319:1239-1245
29. Gutierrez C, Schiff R. HER2: biology, detection and clinical implications. Arch Pathol Lab Med 2011;135: 55-62
30. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128
31. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72: 3179-3184
32. Mizutani T, Onda M, Tokunaga A, et al. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-2088
33. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902
34. Jrgensen J, Hersom M. HER2 as a prognostic marker in gastric cancer-A systematic analysis of data from the literature. J Cancer 2012;3:137-144
35. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091
36. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptint) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831
37. Yu D, Hung M. Overexpression of ErbB2 in cancer and ErbB2-targetting strategies. Oncogene 2000;19: 6115-6121
38. Bang Y, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697
39. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol 2003;21:283-290
40. Kimball KJ, Numnum TM, Kirby TO, et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008;111:95-101
41. Rivkin SE, Muller C, Malmgren JA, et al. A phase I/II study of lapatinib plus carboplatin and paclitaxel in relapsed ovarian and breast cancer. Clinical Ovarian Cancer 2009;2:112-117
42. Weroha SJ, Oberg AL, Ziegler KLA, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011;122:116-120
43. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-4332
44. Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28:1215-1223
45. López-Knowles E, Zardawi SJ, McNeil CM, et al. Cytoplasmic localization of b-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2010;19:301-309
46. Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011;20:119-131
47. Geyer FC, Lacroix-Triki M, Savage K, et al. Beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011;24:209-231
48. Khalil S, Tan GA, Giri DD, et al. Activation status of Wnt/-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One 2012;7:33421
49. White K, Rider D, Kalli KR, et al. Genomics of the NF-kB signaling pathway: hypothesized role inovarian cancer. Cancer Causes Control 2011;22:785-801
50. Yang P, Lorenowicz MJ, Silhankova M, et al. Wnt Signaling Requires Retromer-Dependent Recycling of MIG-14/Wntless in Wnt-Producing Cells. Dev Cell 2008;14:140-147
51. Yang G, Xiao X, Rosen DG, et al. The biphasic role of NF-kB in progression and chemoresistance of ovarian cancer. Clin Cancer Res 2011;17:2181-2194
52. Camp ER, Li J, Minnich DJ, et al. Inducible nuclear factor-kB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004;199:249-258
53. Biswas DK, Shi Q, Baily S, et al. NF-kB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004;101:10137-10142
54. Ahmed K, Cao N, Li J. HER-2 and NF-kB as the targets for therapy-resistant breast cancer. Anticancer Res 2006;26:4235-4243
55. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol 2010;4:404-419
56. de Hoon JPJ, Veeck J, BEPJ Vriens, et al. Tjan-Heijnen VCG. Taxane resistance in breast cancer: A closed HER2 circuit? Biochim Biophys Acta 2012;1825:197-206
57. Zimmerman Z, Moon R, Chien A. Targetting Wnt pathways in disease. Cold Spring Harb Perspect Biol 2012;4:a008086
58. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726
59. Baselga J, Carbonell X, Castan eda-Soto N, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-2171.